Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

With Inflectra, FDA Showed Flexibility On Biosimilar Pediatric Study Plans

Executive Summary

Drug Review Profile: Agency reviewed Celltrion's application while also negotiating an initial Pediatric Study Plan, and it crafted an exemption so that Inflectra and other biosimilars will not need to be studied in Crohn's disease patients as young as two years old.

Advertisement

Related Content

Drug Review Profiles: Behind The Scenes At US FDA
Mapping US FDA's Biosimilar Pathway With Pink Sheet Drug Review Profiles
Sandoz’s Erelzi: Biosimilar Pediatric Labeling Strayed From Enbrel
Pediatric Study Requirements For Cancer Have FDA Support, But Pose Industry Challenges
Inflectra Analytical Data Eased FDA's 'Residual Uncertainty' About Remicade Differences
Inflectra Analytical Data Eased FDA's 'Residual Uncertainty' About Remicade Differences
Evolving Biosimilar Pathway Brings Mid-Review Policy Issues
Biosimilar Naming: FDA Asked Celltrion For Two Kinds Of Suffixes
Inflectra Clinical Development Timeline
Inflectra Reviewers

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS118738

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel